“…Whereas online re-planning for prostate, gynecological and bladder cancer EBRT was applied in silico, the strategy was only used clinically for gynecological cancer treated with BT ( Figure 3) [58,59,61,65-67,70-72,74,78,80,82,83,88-91,94,100, 101,103]. An ART workflow presented in the in silico studies but not in the clinical workflows was offline re-plan/re-optimization, applied during or at the end of EBRT, to correct degradation of the dose distribution from previously delivered fraction [60,63,69,75,76]. In addition to one in silico implementation of online compensation [58], these were the only studies where feedback from delivered dose triggered adaptations.…”